Article Per Year (5 Year)
p-Index From 2021 - 2026
1.152
P-Index
This Author published in this journals
All Journal International Journal of Electrical and Computer Engineering International Journal of Power Electronics and Drive Systems (IJPEDS) IAES International Journal of Artificial Intelligence (IJ-AI) Journal of Information Systems and Informatics Narra J
Md. Rabiul Islam
Rajshahi University of Engineering & Technology
Biochemistry, Genetics & Molecular Biology Computer Science & IT Control & Systems Engineering Electrical & Electronics Engineering Engineering Health Professions Immunology & microbiology Medicine & Pharmacology Public Health

Published : 6 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 2 Documents
Search
Journal : Narra J

 1 
Titer disparity of anti-Spike receptor binding domain SARS-CoV-2 antibody between vaccinated and naturally infected individuals Surawan, Dewa P.; Sumohadi, Duwi; Budhitresna, Anak AG.; Lestari, Putri P.; Dewi, Kartika; Wikananda, Wasudewa; Suwari, Retenra P.; Islam, Md. Rabiul; Te, Haypheng; Rabaan, Ali A.; Masyeni, Sri
Narra J Vol. 2 No. 1 (2022): April 2022
Publisher : Narra Sains Indonesia

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.52225/narra.v2i1.71

Abstract

In conjunction with other health promotion strategies, vaccination of coronavirus disease 2019 (COVID-19) is a strategy to alleviate the burden of infection. The aim of this study was to determine the differences in antibody response strength between individuals who received COVID-19 vaccination and those who had a natural infection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). A cross-sectional study was conducted among post-natural confirmed COVID-19 infection and immunized people in Bali, Indonesia. The vaccination was using Sinovac-CoronaVac with two-weeks interval between the two vaccine doses. To measure the level of anti-Spike receptor binding domain (SRBD) of SARS-CoV-2 antibody, we used Roche electro-chemiluminescence immunoassay (ECLIA) platform. Blood samples were obtained before and 28 days after first immunization in the vaccinated group, as well as two weeks after hospital discharge in the confirmed COVID-19 patients based on real-time reverse transcription polymerase chain reaction (RT-PCR). A total of 58 confirmed COVID-19 patients and 60 vaccinated individuals were included. On the 28th day after the initial vaccination, the seroconversion rate among vaccinated individuals was 91.67%. The mean titer of anti-SRBD SARS-CoV-2 antibody among vaccinated participants was 63.62±82.57 IU/mL (ranged between 0 IU/mL and 250 IU/mL). The mean titer among naturally infected group was 188.47±94.57 IU/mL (ranged between 4.25 IU/mL to 250 IU/mL) regardless the severity of COVID-19. Our data suggested that the titer of anti-SRBD SARS-CoV-2 antibody was significantly higher in naturally infected individuals compared to those who received COVID-19 vaccination (p<0.001). These data suggest that not all individuals vaccinated with Sinovac COVID-19 had protective level of anti-SRBD SARS-CoV-2 antibody and booster dose of heterologous vaccine maybe required.
Pharmaceutical quality evaluation of marketed vildagliptin tablets in Bangladesh based on the United States Pharmacopeia specifications Islam, Md. Rabiul; Daria, Sohel; Ankhi, Arjina A.; Sultana, Sharmin; Rahman, Md. Ashrafur
Narra J Vol. 2 No. 2 (2022): August 2022
Publisher : Narra Sains Indonesia

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.52225/narra.v2i2.84

Abstract

Continuous monitoring of pharmaceutical products is vital because it matters to human health. Here we aimed to assess the quality parameters of commercially available vildagliptin tablets in Bangladesh. We tested the tablets for the content uniformity, hardness, friability, disintegration, dissolution, and potency. Then, we fitted the dissolution data with kinetic models to investigate the release pattern of the studied brands. Moreover, we applied a mathematical model-independent approach to compare the dissolution profiles of the brands. The interchangeability was determined using difference and similarity factors. Weight variation, friability, and hardness were between 150.35±1.26 to 230.8±1.98 mg, 0 to 0.88%, and 47.3±5.09 to 108.1±1.92 N, respectively. All tablets disintegrated within 0.54±2.85 to 7.69±2.14 min in distilled water. The potency of tablets in 0.1 N HCl and PBS (pH 6.8) were between 97.67±2.58 to 105±0.95% and 99±4.63 to 105±1.65%, respectively. The drug release (%) in 0.1 N HCl and phosphate-buffered saline (PBS) (pH 6.8) after 60 min were between 99.37±1.80 to 111.09±0.64% and 96.59±3.52 to 109.57±0.53%, respectively. All the brands complied with the United States Pharmacopeia (USP) specification for physicochemical properties. Also, we observed the drug release patterns of vildagliptin tablets matched with different kinetic models. We found only one substitutable brand with the standard product regardless of the dissolution medium. In-vitro chemical equivalence is not always consistent with bioequivalence. Therefore, continuous evaluation of marketed products is essential to ensure the desired quality.
Co-Authors Ahamed, Bulbul Ahmed, Md. Estiak Al-Islam, Ferdib Ankhi, Arjina A. Balaly, Md. Habibullah Banna, Hasanul Budhitresna, Anak AG. Daria, Sohel Dev, Shuvo Hossain, Md. Amzad Islam, Jahedul Islam, Md. Jahedul Kartika Dewi Khan, M. A. Kumar Godder, Tapan Lestari, Putri P. Makhdum, Niaz Masyeni, Sri Mitra, Bithi Nag, Anindya Rabaan, Ali A. Rahman, Md. Ashrafur Shah, A.M.M. Mubassher Sultana, Sharmin Sumohadi, Duwi Surawan, Dewa P. Suwari, Retenra P. Tanzim, Nujhut Te, Haypheng Ul-Ambia, Ahsan Wikananda, Wasudewa Zahid Hassan